CMS unveiled new details of its new RAPID pathway, which is designed to close the gap between FDA approval and Medicare coverage for breakthrough medical devices. Industry reaction has been largely positive, as medical device companies often sit in “coverage purgatory” for years. The post How CMS Is Tackling ‘Coverage Purgatory’ for Medical Devices appeared first on MedCity News.

Tanvi Patel, vice president and general manager of Amazon Pharmacy, and her co-panelists at the recent Bullseye event, explained why PBMs, payers and doctors are all hampering consumer choice when it comes to patients getting affordable drugs. The post Amazon Pharmacy Executive: Formularies are Anti-Choice appeared first on MedCity News.

Small group insurers are proposing a median 14% premium increase for 2027, driven by rising healthcare costs. The post Small Businesses Could Face Double-Digit Premium Hikes in 2027 appeared first on MedCity News.

Jazz Pharmaceuticals, maker of the blockbuster epilepsy drug Epidiolex, is acquiring Actio Biosciences and its lead drug in pivotal testing for a rare type of epilepsy with no FDA-approved treatments. It’s Jazz’s second epilepsy deal in the past year. The post Jazz Pharma Expands Again in Epilepsy With $820M Actio Bio Acquisition appeared first on MedCity News.

In this episode of the MedCity Pivot Podcast, CVS Health Aetna’s chief digital and technology officer talks about how the insurance business is using AI, especially agentic AI, in healthcare. Point to note: AI is not used in automatic denials of coverage. The post MedCity Pivot: How Aetna is Adopting Agentic AI appeared first on MedCity News.

Drug development isn’t limited by the amount of data we collect, but by our ability to preserve the context, meaning and relationships that transform data into evidence. The post AI in Drug Development is Not a Data Problem — It’s An Evidence Problem appeared first on MedCity News.

Ascension is pushing AI beyond note-taking to tackle the billing, order entry and nursing handoff work still weighing on clinicians after a patient visit ends. The post How to Keep Clinicians Satisfied, the Ascension Way appeared first on MedCity News.

[Sponsored] With home health fraud growing more sophisticated through AI, post-pay audits are no longer enough. Payers must shift to proactive, tech-driven prevention to catch improper claims before paying them. The post Compliance Alone Won’t Fix the Home Health Fraud Problem appeared first on MedCity News.

In addition to pricing the biggest biotech IPO of the week, Braveheart Bio’s underwriters exercised their option to purchase more shares, boosting the clinical-stage company’s total haul to nearly $440 million. Braveheart’s lead drug could be competitive with a blockbuster Bristol Myers Squibb medicine for a type of cardiomyopathy. The post Braveheart Bio’s $382M IPO for Heart Drug Leads a Big Week for Biotech IPOs appeared first on MedCity News.

In this episode, we’re joined by Cheryl Larson, president and CEO of the Midwest Business Group on Health, for our first in-person recording at MedCity News’ recent Bullseye event. The post MedCity FemFwd: Employer Strategies for Women’s Health appeared first on MedCity News.

Hinge Health’s acquisition of Cylinder expands it into GI care, but experts differ on whether employers will favor convenience or specialized solutions. The post Two Differing POVs Emerge About the Hinge-Cylinder Deal appeared first on MedCity News.

Latigo Biotherapeutics will apply the IPO proceeds toward a pipeline that includes a next-generation non-opioid pain drug ready for pivotal testing. BlossomHill Therapeutics also debuted on the Nasdaq, raising cash for cancer drugs designed to address mutations not covered by currently available therapies. The post Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs appeared first on MedCity News.

The problem may not be the investment. It may be the target of the intervention. The post Why Kidney Care’s Biggest Investment Wave Hasn’t Moved Hospital Costs appeared first on MedCity News.

A letter to Medicaid Directors, State Leaders, and other invested collaborators who were awarded Rural Health Transformation (RHT) Grant funding. The post My Wish For Better Care For Americans Living in Rural Areas appeared first on MedCity News.

A bipartisan group of six senators introduced a bill to reform the 340B drug program, locking in hospitals’ use of contract pharmacies and adding new transparency and compliance rules. The legislation would also kill HHS’ contested rebate pilot within a year and replace it with a national data clearinghouse to catch duplicate discounts. The post Bipartisan Lawmakers Are Fighting HHS’ 340B Rebate Push appeared first on MedCity News.